Procurement Summary
Country: USA
Summary: Department of Defense Pharamacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Deadline: 30 Jul 2025
Other Information
Notice Type: Tender
TOT Ref.No.: 123105328
Document Ref. No.: HT9402-25-Q-9304
Financier: Self Financed
Purchaser Ownership: Public
Tender Value: Refer Document
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_details
Login to see detailsTender Details
Description
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: The following August 2025 newly approved drugs will be reviewed:
a. Andembry-Corticosteroids-Immune Modulators-Hereditary Angioedema Agentsb. Arbli - Renin-Angiotensin Antihypertensives - Angiotensin II Receptor Blockersc. Avmapki Fakzynja Co-pack - Oncological Agents - NAd. Ensacove - Oncological Agents - NAe. Ibtrozi - Oncological Agents - NAf. Imuldosa - Targeted Immunomodulatory Biologics - IL-23g. Khindivi - Corticosteroids-Immune Modulators - NAh. Merilog - Insulins - Rapid-Acting Agentsi. nilotinib tartrate-Oncological Agents-Chronic Myelogenous Leukemiaj. Tryptyr - Ophthalmic - Dry Eyek. ustekinumab-aekn - Targeted Immunomodulatory Biologics - IL-23l. Yutrepia - Pulmonary Arterial Hypertension - Prostacyclin Nebulizedm. Zelsuvmi -A...
Active Contract Opportunity
Notice ID : HT9402-25-Q-9304
Related Notice
Department/Ind. Agency : DEPT OF DEFENSE
Sub-tier : DEFENSE HEALTH AGENCY (DHA)
Office: DEFENSE HEALTH AGENCY
General Information
Contract Opportunity Type: Solicitation (Updated)
Updated Published Date: Jul 21, 2025 12:14 pm CDT
Original Published Date: Jul 10, 2025 09:40 am CDT
Updated Date Offers Due: Jul 30, 2025 12:00 pm CDT
Original Date Offers Due: Jul 28, 2025 12:00 pm CDT
Inactive Policy: Manual
Updated Inactive Date: Jan 30, 2026
Original Inactive Date: Jan 28, 2026
Initiative: None
Classification
Original Set Aside: No Set aside used
Product Service Code: 6505 - DRUGS AND BIOLOGICALS
NAICS Code: 325412 - Pharmaceutical Preparation Manufacturing
Place of Performance: San Antonio, Tx 78230 USA
Documents
Tender Notice
A0001-HT9402-25-Q-9304.pdf
A0001-RFQ-HT9402-25-Q-9304-NAD.pdf
A0001-Price-List-Andembry-Corticosteroids-Immune.xlsx
A0001-Price-List-Arbli-Renin-Angiotensin-Antih.xlsx
A0001-Price-List-Avmapki-Fakzynja-Co-pack-Onco.xlsx
A0001-Price-List-Ensacove-Oncological-Agents.xlsx
A0001-Price-List-Ibtrozi-Oncological-Agents.xlsx
A0001-Price-List-Imuldosa-TIB-IL-23.xlsx
A0001-Price-List-Khindivi-Corticosteroids-Immu.xlsx
A0001-Price-List-Merilog-Insulins-Rapid-Acti.xlsx
A0001-Price-List-nilotinib-tartrate-Oncological.xlsx
A0001-Price-List-Tryptyr-Ophthalmic-Dry-Eye.xlsx
A0001-Price-List-ustekinumab-aekn-TIB-IL-23.xlsx
A0001-Price-List-Yutrepia-Pulmonary-Arterial-H.xlsx
A0001-Price-List-Zelsuvmi-Antiinfectives-Misc.xlsx
RFQ-HT9402-25-Q-9304-NAD.pdf
A-1-Price-List-Andembry-Corticosteroids-Immune-Mod.xlsx
A-1-Price-List-Arbli-Renin-Angiotensin-Antihyp.xlsx
A-1-Price-List-Avmapki-Fakzynja-Co-pack-Oncolo.xlsx
A-1-Price-List-Ensacove-Oncological-Agents-N.xlsx
A-1-Price-List-Ibtrozi-Oncological-Agents-NA.xlsx
A-3-Price-List-Imuldosa-TIB-IL-23.xlsx
A-1-Price-List-Khindivi-Corticosteroids-Immune.xlsx
A-1-Price-List-Merilog-Insulins-Rapid-Acting.xlsx
A-1-Price-List-nilotinib-tartrate-Oncological-Agen.xlsx
A-3-Price-List-Tryptyr-Ophthalmic-Dry-Eye.xlsx
A-1-Price-List-ustekinumab-aekn-Targeted-Immun.xlsx
A-1-Price-List-Yutrepia-Pulmonary-Arterial-Hyp.xlsx
A-1-Price-List-Zelsuvmi-Antiinfectives-Miscel.xlsx
Price-Appendix-FAQ-NAD.pdf
DoD-Formulary-Placement-of-FDA-Newly-Approved-Drug.pdf